AIDS Malignancy Consortium
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, AIDS Malignancy Consortium sits in the top decile of US sponsors by registered trial count (#397 of 15,742 sponsors by registered trial count).
AIDS Malignancy Consortium: 45 sponsored US clinical trials, 5 recruiting.
AIDS Malignancy Consortium sponsors 45 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 30 completed. 3 of these trials are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infection, with 7 trials.
Top-decile sponsor footprint
AIDS Malignancy Consortium ranks in the top decile of sponsors by registered trial count (#397 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
30 of 36 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
45 total, page 1 of 1
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
NCT05077527
Trial of Ixazomib for Kaposi Sarcoma
NCT04305691
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
NCT05663502
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
NCT04949464
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
NCT04139304
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
NCT02797470
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
NCT02437851
Nirogacestat in Patients With Kaposi Sarcoma
NCT07539454
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
NCT07662928
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
NCT05510908
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
NCT05784415
Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions
NCT04276935
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
NCT03603808
sEphB4-HSA in Treating Patients With Kaposi Sarcoma
NCT02799485
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
NCT03077451
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
NCT02823327
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
NCT02059499
Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions
NCT02418494
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
NCT02135419
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
NCT01946139
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
NCT01249443
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
NCT01946217
Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
NCT01567722
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
NCT01209325
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
NCT01319526
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
NCT01164722
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
NCT00981097
Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men
NCT00919997
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00427414
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
NCT00686842
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials
NCT00695422
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
NCT00598169
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
NCT00513526
Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00450320
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
NCT00550589
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
NCT00389818
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
NCT00392834
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
NCT00324415
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00090987
Valproic Acid in Treating Patients With Kaposi's Sarcoma
NCT00075777
Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
NCT00066430
Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
NCT00041327
Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma
NCT00005824
Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
NCT00006264
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
NCT00005042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 18 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the AIDS Malignancy Consortium pipeline
5 recruiting of 45 indexed (11% open); 30 completed (67%).
Phase mix: 3 late (III/IV) vs 27 early (I/II) (early-phase heavy).
Top condition: HIV Infection (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AIDS Malignancy Consortium: open-pipeline peers nationwide
Peers matched on 45 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
AIDS Malignancy Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 45 trials (± recruiting share)
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 45 trials · 4% recruiting
- Cambridge Health Alliance · 45 trials · 16% recruiting
- Carilion Clinic · 45 trials · 20% recruiting
- Genmab · 45 trials · 24% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
- Aprea Therapeutics · 11% recruiting · 9 trials
Related
What to do with this AIDS Malignancy Consortium page
45 registered trials is a research-attention snapshot, not an endorsement of AIDS Malignancy Consortium or any single study.
- 5 of AIDS Malignancy Consortium's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infection is the condition AIDS Malignancy Consortium studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AIDS Malignancy Consortium pipeline card: 45 registered trials from official public datasets.Report a data error.